Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.
Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | |||
---|---|---|---|---|---|---|---|---|
Anti Cancer |
Axl/Mer/CSF1R Inhibitor (Q702) |
Immuno Oncology Mono |
||||||
Immuno Oncology Combi Q702+Pembrolizumab (KEYTRUDA®) |
||||||||
Drug Resistant NSCLC |
||||||||
selective CDK7 inhibitor (Q901) |
Solid Tumor |
|||||||
Q901+Pembrolizumab (KEYTRUDA®) |
||||||||
Antibiotics | Cyt bc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||||
Buruli ulcer | ||||||||
Anti Inflammation |
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||||
Oral 5LO Inhibitor |
Asthma |
Candidate | Pre-Clinical | Phase 1 | Phase 2 | ||
---|---|---|---|---|---|
Axl/Mer/ CSF1R Inhibitor (Q702) |
Immuno Oncology Mono |
||||
Immuno Oncology Combi Q702+Pembrolizumab (KEYTRUDA®) |
|||||
Drug Resistant NSCLC |
|||||
Selective CDK7 Inhibitor (Q901) |
Solid Tumor |
||||
Q901+Pembrolizumab (KEYTRUDA®) |
|||||
Cytbc1 Inhibitor (Telacebec, Q203) |
Drug Resistant Tuberculosis |
||||
Buruli ulcer | |||||
Topical 5LO Inhibitor (Q301) |
Atopic Dermatitis |
||||
Oral 5LO Inhibitor |
Asthma |